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Acquired VLDL receptor deficiency in experimental nephrosis
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Acquired VLDL receptor deficiency in experimental nephrosis. Ne-
phrotic syndrome (NS) is commonly associated with elevation of plasma
very low density lipoprotein (VLDL) and triglyceride concentrations.
VLDL receptor (VLDL-R) is a novel protein that specifically binds and
internalizes VLDL particles and is primarily distributed in heart, skeletal
muscle, brain and adipose tissue. Based on these properties, VLDL-R is
thought to play a role in VLDL and triglyceride metabolism. The present
study was undertaken to test the hypothesis that elevation of plasma
VLDL in NS may be, in part, related to VLDL-R deficiency. To this end,
heart and skeletal muscle VLDL-R protein (Western blot) and mRNA
(Northern blot) were measured at various points in the course of
puromycin-induced NS in rats. The results were compared with those
obtained in the placebo-treated normal control animals. The NS group
showed a significant decline in VLDL-R protein (relative to total plasma
membrane protein mass) in the heart and skeletal muscle paralleling the
rise in plasma VLDL and triglyceride concentrations. The fall in VLDL-R
protein was accompanied by a parallel decline in VLDL-R mRNA in the
heart but not skeletal muscle. VLDL-R protein was directly related to
proteinuria and inversely related to plasma VLDL and triglyceride
concentrations. In conclusion, puromycin-induced NS in rats is associated
with profound reduction in heart and skeletal muscle VLDL receptor
protein. Acquired VLDL-R deficiency, shown for the first time here, may
contribute to elevation of plasma concentration of triglyceride-rich VLDL
in the nephrotic rat. Recognition of this abnormality reveals another
dimension of the complex dysregulation of lipid metabolism in NS. The
precise mechanism responsible for NS-induced VLDL-R deficiency in this
model is not clear and awaits further investigation.
Nephrotic syndrome (NS) results in profound dysregulation of
lipid metabolism and marked quantitative and qualitative abnor-
malities of plasma lipoprotein profile. In this regard, hepatic
HMG-CoA reductase expression is inappropriately increased
while those of cholesterol 7a-hydroxylase (the rate-limiting en-
zyme in cholesterol conversion to bile acids), LDL receptor, and
lipoprotein lipase (LPL) are decreased in rats with NS [1—4].
Plasma concentrations of LDL, VLDL, IDL, Lp(a), total choles-
terol and triglycerides are increased while the HDL-to-LDL ratio
is decreased in humans with NS [5—71.
VLDL receptor (VLDL-R) is a newly recognized member of
the LDL receptor (LDL-R) family that binds and internalizes
VLDL but not LDL [8, 9]. Tissue distribution of VLDL-R is
distinctly different from that of LDL-R. LDL-R is predominantly
expressed in the liver, ovaries and adrenal cortex where it plays a
major role in delivering cholesterol ester-rich lipoproteins. How-
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ever, like LPL, VLDL-R is largely expressed in skeletal muscle,
heart and adipose tissue, which utilize fatty acids as a major
source of energy [8, 10, 11]. Gene expression of VLDL-R in
skeletal muscle is down-regulated in experimental hypothyroidism
and up-regulated in hyperthyroidism [91. Based on its binding
specificity and tissue distribution, VLDL-R appears to play an
important role in the metabolism of triglyceride-rich VLDL
particles. We, therefore, hypothesized that elevation of plasma
VLDL and triglyceride levels in NS may be, in part, due to
down-regulation of VLDL-R. To test this hypothesis, we exam-
ined expression of this protein in heart and skeletal muscle during
the course of puromycin-induced NS in rats. The results were




Male Sprague-Dawley rats (Harlan Sprague Dawley, Inc., In-
dianapolis, IN, USA) weighing 180 to 200 g were used. They were
housed in a temperature and light-controlled space with 12-hour
light (500 lux) and 12-hour dark ( 5 lux) cycles and were allowed
free access to food (Purina Rat Chow, Purina Mills Inc., Brent-
wood, MO, USA) and water. Animals were randomized into the
nephrotic (NS) and normal control groups. The rats randomized
to the NS group were given sequential intraperitoneal injections
of puromycin aminonucleoside on day 0 (130 mg/kg) and day 14
(60 mg/kg). The rats placed in the control group received placebo
injections (5% dextrose in water). Subgroups of rats were studied
on days 1, 5, 20 and 30. Twenty-four hour urinary protein
excretion, creatinine clearance and plasma concentrations of
cholesterol, triglycerides, albumin and creatinine were deter-
mined using standard laboratory methods. Plasma VLDL-choles-
terol concentration was calculated by subtracting the sum of
LDL-cholesterol and HDL-cholesterol from total plasma choles-
terol value. Under sodium pentobarbital anesthesia (50 mg/kg,
i.p.), the animals were sacrificed and the heart and soleus muscles
were immediately removed for measurements of VLDL-R
mRNA.
Polymerase chain reaction
Polymerase chain reaction (PCR) was used to prepare a partial
eDNA probe for rat VLDL-R. To this end, two oligonucleotide
primers were used to ampli!' a 502 bp rat VLDL-R eDNA
fragment. The primers employed included VLDL-R1 (nucleotide
361-383:5' GATGGCAGTGACGAGAAGAACT 3') and VLDL-
R2 (nucleotide 841-863: 5' CAAGAGACTCGTCTGA]TGGTC
3'). The compositions of these primers were derived from the
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published sequence for rat VLDL-R [9]. First strand cDNA was
synthesized from 1 g rat heart poly(A) RNA (used as template)
employing a cDNA cyclic kit (Invitrogene, San Diego, CA, USA).
The cDNA produced was then amplified by PCR in 50 jtI of a
solution containing 10 mrvt Tris-HCI, 50 ffiM KCI, 1.5 mM MgC1,
200 M dNTP mixture (consisting of dATP, dCTP, dGTP and
dTTP), I U Taq polymerase and 1 jtM of each primer. PCR
amplification was carried out for 30 cycles, each consisting of the
following steps: 94°C, one minute; 55°C, one minute; and 72°C,
one minute. The PCR products were separated on 1% agarose
gel, and the band corresponding to the 500 base pairs was cut,
isolated with a Gene-Clean 228 II Kit (Qiagen Inc., Chatsworth,
CA, USA), then ligated to a PCR 228 II vector using a TA cloning
kit (Invitrogene). Positive insert was sequenced by Sequenase
Version 2.0 Kit (United States Biochemical Co., Cleveland, OH,
USA) on double stranded DNA. To prepare the probe, approxi-
mately 0.5 Kb VLDL-R eDNA insert was excised by EcoRI from
the above clone.
RIVA preparation and Northern blot analysis
At the conclusion of each study period, the rats were killed
between the hours of 9 and 11 a.m. The tissues were removed
immediately, frozen in liquid nitrogen and stored at —70°C until
processed. Total RNA was prepared from 1 g of tissue with
RNAzo1 using the manufacture's recommended procedure (Tel-
Test Inc., Friendswood, TX, USA) as previously described [12].
RNA concentration was determined from the absorbance at 260
nm using a spectrophotometer (Gene-Quat, Bio-Rad, Hercules,
CA, USA). Twenty-five microgram aliquots of total RNA were
denatured in 2.2 M formaldehyde at 65°C for 15 minutes and run
on 1.0% agrose/2.2 M formaldehyde gel at 46 V for four hours.
The separated RNA was transferred to the nylon membrane
(Zeta probe, Bio-Rad) by capillary blotting in 6 X SSC buffer
overnight and immobilized by UV irradiation (Ultraviolet
Crosslinker; Fisher Scientific, Pittsburgh, PA, USA). The mem-
brane was incubated at 65°C in a solution containing 5 X SSPE,
5 X Denhard's, 1% SDS and 100 jg!ml salmon sperm DNA for
two hours. The eDNA probe for rat glyceraldehyde phosphate
dehydrogenase (GAPDH) (1.3 Kb PstI fragment) was obtained
from American Type Culture Collection (Rockville, MD, USA).
The eDNA probe for VLDL-R was prepared as described above.
The probes were labeled with [32P] dCTP (3000 Ci/mmol; New
England Nuclear Inc., Boston, MA, USA) by the random primer
method (Promega Inc., Madison, WI, USA). Hybridization was
carried out at 60°C in a prehybridization solution with 32P labeled
cDNA. The blots were washed twice in 2 x SSPE/0.5% SDS
solution at room temperature, twice in 1 )< SSPE/0.5% SDS
solution at 37°C, and twice in 0.1 X SSPE/0.5% SDS solution at
65°C, for 15 minutes each. The washed blots were exposed to
X-ray film (New England Nuclear Inc.) at —80°C for 2 to 6 hours
for GAPDH and 2 to 3 days for VLDL-R. The autoradiographs
were scanned with a laser densitometer (Molecular Dynamics,
Sunnyvale, CA, USA) to determine relative mRNA levels. The
values obtained for constitutively expressed GAPDH gene were
used as an internal control.
Monoclonal antibody production
The TgG-6A6 hybridoma cell line producing mouse monoclonal
antibody recognizing the cytoplasmic domain of the VLDL-R was
purchased from ATCC. The hybridoma was grown in Dulbecco's
Modified Eagle's Medium (DMEM; Gibco BRL Products, Gaith-
ersburg, MD, USA) with 10% FCS. The cells were then subcul-
tured and allowed to overgrow until cell death occurred. The
supernatant containing the antibody was harvested and stored.
This antibody recognizes VLDL-R present in various tissues and
several species including rats.
Western blot analysis
These experiments were carried out to determine the plasma
membrane contents of VLDL-R in the target tissues of the study
animals. Muscle and heart plasma membranes were prepared as
follows: Frozen rat tissues were homogenized in 20 mivi Tris-HCI
(pH 7.5) containing 2 msi MgCI2, 0.2 M sucrose, 5 mM phenyl-
methylsulfonyl fluoride, 5 jsg/ml leupeptin, 10 ig/ml aprotinin and
3 jig/mI pepstatin A. The crude extracts were centrifuged at
3000 >< g for 10 minutes at 4°C. The supernatant was then
centrifuged at 35,000 x g for 30 minutes. The crude membrane
preparations were washed with the above buffer and centrifuged
at 35,000 X g for 45 minutes at 4°C. Protein concentration was
determined using a Bio-Rad Kit (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). Bovine serum albumin was used to construct
the standard curve for this assay. One-hundred microgram protein
aliquots were size-fractionated on 4 to 12% Tris-glycine gel
(Novex, San Diego, CA, USA) at 120 V for two hours. After
electrophoresis, proteins were transferred to Hybond-ECL mem-
brane (Amersham Life Science Inc., Arlington Heights, IL, USA).
The membrane was incubated for one hour in buffer A (1 X PBS,
0.1% Tween-20 and 8% nonfat milk) and then overnight in the
same buffer to which 1:10 dilution of the above antibody prepa-
ration were added. The membrane was washed once for 15
minutes then twice for five minutes in 1 X PBS, 0.1% Tween-20
prior to a 1-hour incubation in buffer A to which diluted (1:1000)
horseradish peroxidase-linked sheep anti-mouse IgG (Amer-
sham) was added. The washes were repeated before the mem-
branes were developed with chemiluminescent agents (ECL,
Amersham) and subjected to luminography for one hour. The
optical densities of the bands were then measured by a laser
densitometer. Given the constancy of the total loading dose of
protein across all experiments, the VLDL-R protein data are
automatically normalized against plasma membrane total protein
mass. Thus, all data represent relative VLDL-R protein per total
membrane protein mass.
Statistical analyses
Analyses of variance, regression analysis and Students' t-test
were used in statistical evaluation of the data which are expressed




Data are depicted in Table 1. The NS group exhibited marked
proteinuria, hypoalbuminemia, hypercholesterolemia, hypertri-
glyceridemia and significant elevation of plasma VLDL-choles-
terol concentration. However, serum creatinine concentration and
creatinine clearance were normal in the NS group. Therefore, the
model employed here showed NS without renal insufficiency.
Proteinuria became first manifest beyond day 5 and steadily
increased through day 20 reaching a plateau thereafter.
S. -
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Table 1. Serum concentrations of total cholesterol, VLDL cholesterol,
triglyceride and creatinine and 24-hour urine protein excretion and
creatinine clearance in the normal control (NL) rats and rats with
nephrotic syndrome studied at day 30 (NS)
NL(N = 6) NS (N = 6) P
Urine protein mg/24 hrs 6.9 0.9 269.2 19.5 <0.001
Serum cholesterol mg/dl 71.6 3.4 296.6 17.0 < 0.001
Serum VLDL mg/dl 7.8 0.8 46.5 6.0 <0.001
Serum triglyceride mg/dl 47.2 6.6 227.6 24.6 <0.001
Serum albumin mg/dl 3.7 0.2 2.2 0.1 <0.001
Serum creatinine mg/dl 0.6 0.1 0.5 0.1 NS
Ccr mI/mm 1.2 0.2 1.3 0.1 NS
1 2 3 4 5
Fig. 1. A representative autoradiograph of the Northern blot of soleus muscle
and heart J/LDL receptor (VLDL-R) and the corresponding GAPDH in the
normal control (NL) (lane 1) and the nephrotic rats (NS) at days I (lane 2),
5 (lane 3), 20 (lane 4) and 30 (lane 5). Total RNA (15 rg/lane) was isolated
from tissues as described in the Methods section, and separated by
electrophoresis on 1.0% agarose/2.2 M formaldehyde gel. RNA was
transferred to nylon membrane and hybridized with the 32P-labeled 0.5 Kb
eDNA to rat VLDL-R mRNA and 1.3 Kb eDNA to rat GAPDH mRNA
used to control for possible variations in the loading dose.
VLDL-R
Muscle Heart
1 2 1 2
— 140 kDa
Fig. 2. Representative Western blot of soleus muscle and heart VLDL-R in
the normal control (NL) and nephrotic (NS) rats at day 30. Plasma
membrane polypeptides (100 jLgllane) isolated from muscle and heart
were size-fractionated on 4 to 12% Tris glycine gel, transferred to ECL
membrane and immunoblotted using mouse monoclonal VLDL-R anti-















Fig. 3. Comparison of soleus muscle (A) and heart (B) VLDL-R protein in
the nephrotic rats (NS) and the normal control group (NL) obtained on day
30. Data are given as mean SCM. N = 6. P < 0.01.
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VLDL-R mRNA and protein
Skeletal muscle. Data are illustrated in Figures 1, 2, 3 and 4.
Skeletal muscle VLDL-R protein in the NS group declined
markedly to values which were 70% below that found in the
normal control group. In contrast, skeletal muscle mRNA in the
NS group remained virtually unchanged during the observation
period.
Heart. Data are shown in Figures 1, 2, 3 and 4. The heart
VLDL-R mRNA was significantly reduced in the NS group. This
was accompanied by a nearly 70% fall in the heart tissue VLDL-R
protein as compared to the value observed in the normal control
group. Thus, the NS group showed an equally severe reduction in
VLDL-R protein in the heart and skeletal muscle even though
reduced mRNA levels were found in the heart hut not skeletal
muscle.
Acute effect of puromycin. Data are presented in Figure 5. In an
attempt to dissect the acute effect of puromycin from that of the
associated proteinuria, subgroups of animals were studied on day
I when proteinuria was absent. We found virtually no change in
VLDL-R mRNA or protein at this point despite recent exposure
to high levels of puromycin.
Correlations. Data are shown in Table 2. Serum triglyceride and
VLDL concentrations were inversely related to the heart and
skeletal muscle VLDL-R protein in the study groups. Cardiac and
skeletal muscle VLDL-R proteins were inversely related to the
degree of proteinuria and directly related to serum albumin
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Fig. 5. A. Relative optical density of VLDL-R mRNA normalized against
that of the corresponding constitutively expressed GAPDH in the heart and
skeletal muscle of pre-nephrotic rats obtained 24 hours after administration of
130 mg/kg puromycin •) as compared with those obtained in placebo-
treated normal controls (LI). B. Optical densities of Western blots of
skeletal muscle and heart VLDL-R protein in the pre-nephrotic rats
obtained 24 hours after puromycin (•) or placebo (LI) injection. Data are
given as mean SEM. N = 4 in each group.
Table 2. Correlations between serum triglycerides, VLDL, albumin and
urine protein excretion versus heart and muscle VLDL-R protein and
mRNA in the study groups
Muscle Heart
0 , I I I Ir I
01 5 10 20 30
Time, days
Fig. 4. Longitudinal measurements of soleus muscle (A) and heart (B)
VLDL-R mRNA (normalized against corresponding GAPDH mRNA) in the
normal control (I) and nephrotic () rats at days 1, 5, 20 and 30. Data are
given as mean SEM. N = 6. P < 0.01.
mRNA and protein in the heart, suggesting concordance between
the transcript and the translation product in this organ.
Discussion
As expected, the nephrotic animals employed in the present
study showed a marked increase in serum VLDL and triglyceride
concentrations. This was associated with a significant fall in
VLDL-R protein expression by the heart and skeletal muscle.
Serum VLDL and triglyceride concentrations showed a strong
inverse correlation with both skeletal muscle and heart VLDL-R
protein values. This observation suggests, although it does not
prove, that acquired VLDL-R deficiency may, in part, contribute
to elevation of serum VLDL and triglyceride concentrations in
this model of NS. In view of the specific affinity of VLDL-R for






Heart VLDL-R r = —0.9 r = 0.91 r = —0.86 r = —0.8
mRNA P < 0.01 P < 0.01 P < 0.01 P < 0.01
Heart VLDL-R r = —0.93 r = 0.85 r = —0.84 r = —0.89
Protein P < 0.01 P < 0.01 P < 0.01 P < 0.01
Muscle VLDL-R r = —0.92 r = 0.91 r = —0.92 r = —0.91
Protein P < 0.01 P < 0.01 P < 0.01 P < 0.01
heart, brain and adipose tissue which use fatty acids as a major
source of energy, it is entirely plausible that its deficiency may
contribute to elevation of circulating VLDL and triglycerides in
this condition. In fact, we have recently found a severe VLDL-R
deficiency in rats with chronic renal insufficiency (CRF), a condi-
tion which is marked by hypertriglyceridemia, elevated plasma
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VLDL concentration and impaired VLDL clearance [131. Thus,
the presence of VLDL-R deficiency in CRF and NS, which are
both associated with impaired VLDL metabolism, supports its
possible role in the pathogenesis of the associated dyslipidemias.
The observed 2.5-fold reduction in VLDL-R protein of the
cardiac tissue was accompanied by a reduction in VLDL-R
mRNA of nearly the same magnitude. This observation suggests
that the NS-induced down-regulation of cardiac VLDL-R level in
this model may occur at the mRNA level. Interestingly, the
threefold reduction in skeletal muscle VLDL-R protein was
observed in the face of virtually normal mRNA levels in the NS
animals. This phenomenon may be due to either decreased
translational efficiency, increased VLDL-R protein catabolism or
a combination thereof. Further studies are required to address
this issue.
The available data on physiological regulation of VLDL-R
expression are presently limited, and the issue is under active
investigation by several laboratories. In a recent study, Jokinen
and their associates showed that VLDL-R protein expression by
skeletal and cardiac muscles is up-regulated by excess thyroid
hormone administration and is down-regulated by thyroidectomy
in rats [9j. However, VLDL-R protein did not change with either
starvation or refeeding [VI. Although NS is associated with urinary
excretion of thyroid hormones along with their binding proteins,
patients and experimental animals with NS are generally euthy-
roid [14, 151. Thus, hypothyroidism does not appear to be a major
cause of NS-induced down-regulation of this receptor. However,
the possible partial contribution of a subtle hypothyroidism to this
condition cannot be excluded with certainty and needs further
investigation.
The observed reduction in VLDL-R protein in the heart and
skeletal muscle in the NS animals is unlikely to be due to an acute
effect of puromycinperse. This is because no significant reduction
in VLDL-R protein was observed 24 hours after puromycin
injection. Instead, significant reductions in VLDL-R protein were
observed late in the course of NS when puromycin exposure was
temporarlly remote. Moreover, expressions of certain other pro-
teins are significantly increased or unaltered in this model [1, 21,
a phenomenon that cannot be explained by the inhibitory effect of
puromycin on protein metabolism.
As noted above, chronic renal insufficiency leads to profound
down-regulation of VLDL-R [131. Similarly, CRF is associated
with down regulation of LPL and hepatic lipase which are both
involved in VLDL and triglyceride metabolism [16—181. The
observed reduction in VLDL-R expression in the NS animals
employed here is not due to renal insufficiency. This is because the
NS model employed here is not associated with renal insufficiency
as evidenced by normal serum creatinine concentration and
creatinine clearance in these animals.
In conclusion, the rise in plasma VLDL and triglyceride con-
centrations in the course of puromycin-induced NS in rats was
accompanied by an impressive 2.5- to threefold reduction in heart
and skeletal muscle VLDL receptor protein. Given the specific
ligand binding property of this novel receptor, its deficiency in NS
animals may be, in part, responsible for impaired VLDL catabo-
lism in this model. The precise mechanism leading to down-
regulation of VLDL-R in puromycin-induced NS is presently
uncertain and awaits further investigation.
Reprint requests to N.D. Vaziri, M.D., Division of Nephrolo, UCI
Medical Center, 101 The City Drive, Orange, California 92668, USA.
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